Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02812667 | Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) | PHASE1 | COMPLETED | 18 | — | — | Aug 29, 2016 | Oct 24, 2025 | Nov 12, 2025 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Nivolumab + Plinabulin | EXPERIMENTAL | Nivolumab 240mg IV, day 1 and 15 until disease progression Plinabulin 3.5mg/m2, 20mg/m2, 30 mg/m2 or 40mg/m2 IV, day 1,8 and 15 until disease progression |
| Name | Type | Description |
|---|---|---|
| Nivolumab + Plinabulin | DRUG | - |
Inclusion Criteria: * Subjects with histologically or cytologically-confirmed metastatic NSCLC whose disease progressed during/after treatment with at least one platinum-containing chemotherapy regimen. * At least 1 prior systemic therapy for metastatic disease. Adjuvant chemotherapy or concurrent ...